Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.59 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.56 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.56 |
| ▸ | GNPAT | O15228 | 1/20 | 0.45 |
| ▸ | GGH | Q92820 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468801 | 1.00 | FOLH1 (0.59) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL468800 | 1.00 | FOLH1 (0.59) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL19185486 | 0.87 | FOLH1 (0.46) | FOLH1NAALAD2RIMKLAGNPATNOD1 | |
| SCHEMBL9074250 | 0.87 | FOLH1 (0.46) | FOLH1NAALAD2RIMKLAGNPATNOD1 | |
| SCHEMBL29822167 | 0.85 | FOLH1 (0.66) | FOLH1NAALAD2RIMKLAGNPATNOD1 | |
| SCHEMBL24302141 | 0.83 | FOLH1 (0.43) | FOLH1NAALAD2RIMKLAGNPATNOD1 | |
| SCHEMBL18272425 | 0.82 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL15958206 | 0.82 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL18082026 | 0.82 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL19718595 | 0.82 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLAGNPATGGH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2259068-B1 | Capture compounds and methods for analyzing the proteome | CAPROTEC BIOANALYTICS GMBH (DE) | 2013-08-14 | — | — | EP | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | FOLH1 3454/4885NAALAD2 289/4885RIMKLA 2585/4885 |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CHLSN, PTMS, SRMS | FOLH1 2698/4885NAALAD2 927/4885RIMKLA 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.